Dr. Reddy's Laboratories launches Sodium Nitroprusside Injection

Dr. Reddy’s Laboratories announced the launching of Sodium Nitroprusside injection, 50 mg/2 mL (25 mg/mL) single-dose Vial in the U.S. Market. It is the therapeutic generic equivalent of Nitropress (sodium nitroprusside) Injection, 50 mg/2ml vial, belonging to Hospira, Inc. and was launched post the USFDA approvals.

Dr. Reddy's Sodium Nitroprusside Injection is available in single-dose 50 mg/2 ml (25 mg/ml) vials. As a part of the warning, patients must consider that Sodium Nitroprusside Injection is not suitable for direct injection. The solution must be further diluted in sterile 5 per cent dextrose injection before infusion. It is primarily used for immediate control of high blood pressure during a hypertensive crisis.

As per IQVIA Health, Nitropress brand and generics had US sales of approximately US$ 8 million MAT for the most recent twelve months ending in October 2019.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products, the company offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilar, and differentiated formulations. Its major therapeutic areas of focus include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

On Monday, the stock of the company closed at Rs 2,883, down by 0.40 per cent or Rs 11.65 per share. The 52-week high is Rs 2,990 and 52-week low is Rs 2,065.30 on BSE.